Company Encyclopedia
View More
name
KELUN PHARMA
002422.SZ
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications.
3.159 T
002422.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking77/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.20%B
    • Profit Margin9.10%B
    • Gross Margin45.43%B
  • Growth ScoreD
    • Revenue YoY-18.66%E
    • Net Profit YoY-43.80%D
    • Total Assets YoY4.46%C
    • Net Assets YoY9.12%B
  • Cash ScoreC
    • Cash Flow Margin1098.71%B
    • OCF YoY-18.66%E
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreB
    • Gearing Ratio28.63%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Guojin Securities: The differentiation in the pharmaceutical industry track continues in Q3 2025, with accelerated release of innovative drugs

    Guojin Securities released a research report indicating that the overall performance of the pharmaceutical industry will be stable in the third quarter of 2025, with profits showing some improvement. Pharma companies are exhibiting differentiated performances, with large enterprises making faster progress in innovation and transformation performing better. Biotech companies are rapidly increasing their volume, approaching breakeven. From the first to the third quarter of 2025, the overall revenue and net profit attributable to the parent company in the pharmaceutical sector are expected to grow at rates of -3% and -8%, respectively, while the growth rates for the third quarter of 2025 are projected to be -1% and +17%

    Zhitong·
    SZ
    002653
    -0.38%
    SZ
    002422
    -1.09%
    Zhitong·
    SZ
    002653
    -0.38%
    SZ
    002422
    -1.09%

    On the morning of the second day of the 2025 National Conference: Concentrated negotiations on tumor drugs, Astrazeneca, Roche, and others participate

    From the on-site negotiations of the national medical insurance catalog and the price negotiations for innovative drugs with commercial insurance in 2025, it was learned that the second day of the national negotiations in 2025 began around 8 a.m. The main varieties for negotiation today are anti-tumor drugs and chronic disease medications. Representatives from companies such as AstraZeneca, KELUN PHARMA, Roche, and Sanofi have entered the negotiation venue. A representative from a negotiating company expressed their personal opinion to reporters, stating, "The ones with a higher possibility will likely be discussed first, while those with a slightly lower possibility will be arranged later."

    Zhitong·
    US
    SNY
    -1.59%
    US
    AZN
    -0.90%
    US
    RHHBY
    -1.47%
    Zhitong·
    US
    SNY
    -1.59%
    US
    AZN
    -0.90%
    US
    RHHBY
    -1.47%

    KELUN PHARMA: The net profit for the third quarter was 200 million yuan, a year-on-year decrease of 70.18%

    KELUN PHARMA announced that its revenue for the third quarter was 4.193 billion yuan, a year-on-year decrease of 15.48%; net profit was 200 million yuan, a year-on-year decrease of 70.18%. Revenue for the first three quarters was 13.277 billion yuan, a year-on-year decrease of 20.92%; net profit was 1.201 billion yuan, a year-on-year decrease of 51.41%

    Zhitong·
    SZ
    002422
    -1.09%
    Zhitong·
    SZ
    002422
    -1.09%

    KELUN PHARMA: The company's products are expected to win bids in the 11th batch of national centralized drug procurement

    KELUN PHARMA announced that the company and its subsidiaries participated in the bidding for the 11th batch of national centralized drug procurement, with plans to win bids for Maleate Aflibercept Tablets, Aflibercept Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets. The sales revenue for Aflibercept Ethanolamine Tablets in 2024 is expected to be 19.9423 million yuan, while the sales revenue for Compound Sodium Acetate Ringer's Injection is 17.7263 million yuan for 2023 and 7.9331 million yuan for 2024

    Zhitong·
    SZ
    002422
    -1.09%
    Zhitong·
    SZ
    002422
    -1.09%

    Kelun Pharma Gets Nod for Trastuzumab; Shares Up 4%

    Kelun Pharma Gets Nod for Trastuzumab; Shares Up 4%

    marketscreener·
    SZ
    002422
    -1.09%
    marketscreener·
    SZ
    002422
    -1.09%
    © 2025 Longbridge｜Disclaimer